It is not a drug, food, or cosmetic, and is not intended for human or veterinary consumption, diagnosis, treatment, or prevention of any condition
Some may increase to 1000 mg daily, but this should always be done under medical guidance
Tirzapeptide operates as a dual incretin receptor agonist, targeting two specific hormones: glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)
Among 8,184 adults without diabetes who initiated injectable semaglutide or tirzepatide for obesity, 4,492 had a dispensing gap longer than 90 days within the first year
Advantage : Semaglutide Side Effect Profile# MET-097i : Limited safety data from Phase 1/2 and Phase 2b trials
Sources Haufroid, V., Lauwerys, R